MedTrace Logo

A Study of Atorvo+™ in Healthy Adult Participants

NCT06615284 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-12-19

No results posted yet for this study

Summary

A Phase 1 study will assess the safety, tolerability, and pharmacokinetics of Atorvo+™ in healthy adult participants.

.

Conditions

Interventions

DRUG

Atorvo+™ (Arm1)

Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).

DRUG

Atorvo+™ +CBD (Arm 2)

Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).

DRUG

Atorvo+™ +CBD (Arm 3)

Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).

Sponsors & Collaborators

  • Indication Bioscience LLC

    lead INDUSTRY

Principal Investigators

  • James E Smeeding · President, Indication Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-28
Primary Completion
2025-05-14
Completion
2025-06-10

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06615284 on ClinicalTrials.gov